(NASDAQ: NERV) Minerva Neurosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.9%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.5%.
Minerva Neurosciences's earnings in 2026 is -$14,027,562.On average, 4 Wall Street analysts forecast NERV's earnings for 2026 to be -$5,670,953, with the lowest NERV earnings forecast at -$7,196,215, and the highest NERV earnings forecast at -$3,965,261. On average, 4 Wall Street analysts forecast NERV's earnings for 2027 to be -$4,315,631, with the lowest NERV earnings forecast at -$4,523,335, and the highest NERV earnings forecast at -$4,038,692.
In 2028, NERV is forecast to generate -$1,783,319 in earnings, with the lowest earnings forecast at -$1,713,384 and the highest earnings forecast at -$1,835,769.